Isocitrate Dehydrogenase 2 Inhibitor [EPC]: Side Effects & Safety Data for 2 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Isocitrate Dehydrogenase 2 Inhibitor [EPC] includes 2 drugs with a combined 3,968 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
2
Drugs in Class
3,968
Combined Reports
All Isocitrate Dehydrogenase 2 Inhibitor [EPC] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| ENASIDENIB | Idhifa | 3,704 | 967 | 1,143 | 26.1% |
| VORASIDENIB | VORANIGO | 264 | 6 | 57 | 2.3% |
Common Side Effects in Isocitrate Dehydrogenase 2 Inhibitor [EPC] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Death | 650 | 650 |
| Fatigue | 229 | 6 |
| Nausea | 213 | 6 |
| Off label use | 213 | 26 |
| Acute myeloid leukaemia | 163 | 95 |
| Diarrhoea | 156 | 1 |
| Hospitalisation | 149 | 2 |
| Decreased appetite | 122 | 3 |
| Drug ineffective | 115 | 7 |
| Platelet count decreased | 113 | 3 |